Bauza, Karolis;
Malinauskas, Tomas;
Pfander, Claudia;
Anar, Burcu;
Jones, E. Yvonne;
Billker, Oliver;
Hill, Adrian V. S.;
Reyes-Sandoval, Arturo
Efficacy of a Plasmodium vivax Malaria Vaccine Using ChAd63 and Modified Vaccinia Ankara Expressing Thrombospondin-Related Anonymous Protein as Assessed with Transgenic Plasmodium berghei Parasites
Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
Efficacy of a Plasmodium vivax Malaria Vaccine Using ChAd63 and Modified Vaccinia Ankara Expressing Thrombospondin-Related Anonymous Protein as Assessed with Transgenic Plasmodium berghei Parasites
Beteiligte:
Bauza, Karolis;
Malinauskas, Tomas;
Pfander, Claudia;
Anar, Burcu;
Jones, E. Yvonne;
Billker, Oliver;
Hill, Adrian V. S.;
Reyes-Sandoval, Arturo
Erschienen:
American Society for Microbiology, 2014
Erschienen in:Infection and Immunity
Sprache:
Englisch
DOI:
10.1128/iai.01187-13
ISSN:
0019-9567;
1098-5522
Entstehung:
Anmerkungen:
Beschreibung:
<jats:title>ABSTRACT</jats:title>
<jats:p>
<jats:named-content content-type="genus-species">Plasmodium vivax</jats:named-content>
is the world's most widely distributed malaria parasite and a potential cause of morbidity and mortality for approximately 2.85 billion people living mainly in Southeast Asia and Latin America. Despite this dramatic burden, very few vaccines have been assessed in humans. The clinically relevant vectors modified vaccinia virus Ankara (MVA) and the chimpanzee adenovirus ChAd63 are promising delivery systems for malaria vaccines due to their safety profiles and proven ability to induce protective immune responses against
<jats:named-content content-type="genus-species">Plasmodium falciparum</jats:named-content>
thrombospondin-related anonymous protein (TRAP) in clinical trials. Here, we describe the development of new recombinant ChAd63 and MVA vectors expressing
<jats:named-content content-type="genus-species">P. vivax</jats:named-content>
TRAP (PvTRAP) and show their ability to induce high antibody titers and T cell responses in mice. In addition, we report a novel way of assessing the efficacy of new candidate vaccines against
<jats:named-content content-type="genus-species">P. vivax</jats:named-content>
using a fully infectious transgenic
<jats:named-content content-type="genus-species">Plasmodium berghei</jats:named-content>
parasite expressing
<jats:named-content content-type="genus-species">P. vivax</jats:named-content>
TRAP to allow studies of vaccine efficacy and protective mechanisms in rodents. Using this model, we found that both CD8
<jats:sup>+</jats:sup>
T cells and antibodies mediated protection against malaria using virus-vectored vaccines. Our data indicate that ChAd63 and MVA expressing PvTRAP are good preerythrocytic-stage vaccine candidates with potential for future clinical application.
</jats:p>